Lyra Therapeutics Director Departs, Officer Compensation Noted
Ticker: LYRA · Form: 8-K · Filed: Aug 1, 2025 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-departure, officer-compensation, governance
TL;DR
Lyra Therapeutics director David Brown is out, and exec pay details are in.
AI Summary
Lyra Therapeutics, Inc. announced on August 1, 2025, the departure of Dr. David L. Brown from its Board of Directors. The company also reported on compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are important for understanding executive incentives.
Risk Assessment
Risk Level: low — This filing primarily reports routine corporate governance changes and compensatory arrangements without disclosing significant financial events or strategic shifts.
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- Dr. David L. Brown (person) — Departing Director
- August 1, 2025 (date) — Date of Report
FAQ
Who has departed from Lyra Therapeutics' Board of Directors?
Dr. David L. Brown has departed from Lyra Therapeutics' Board of Directors as of August 1, 2025.
What is the effective date of the reported changes?
The earliest event reported is dated August 1, 2025.
What is the primary business address of Lyra Therapeutics?
The primary business address of Lyra Therapeutics is 480 Arsenal Way, Watertown, MA 02472.
What is the SIC code for Lyra Therapeutics?
The Standard Industrial Classification (SIC) code for Lyra Therapeutics is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
What other information is disclosed regarding officer compensation?
The filing indicates that compensatory arrangements of certain officers are being reported, but specific details or dollar amounts are not provided in this excerpt.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 1, 2025 by Dr. David L. Brown regarding Lyra Therapeutics, Inc. (LYRA).